AzTrials
AzTrials

Multiple SclerosisNCT02851342

GTA-MEG as a Biomarker for Cognition in MS

An observational study of Multiple Sclerosis, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this study, 100 persons with Multiple Sclerosis and 50 matched controls will be examined with magnetoencephalography (MEG), magnetic resonance imaging (MRI) and cognitive tests. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Multiple Sclerosis
How many people
159 participants
Where
1 siteBelgium
Study dates
Apr 2016to Jan 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: patients with multiple sclerosis

Who may be able to join

  • Multiple sclerosis according to the modified McDonald criteria
  • Expanded Disability Status Scale (EDSS) below 6.0
  • Providing informed consent
  • Age between 18 and 55 years

Who cannot join

  • Major medical or psychiatric pathology that potentially influences cognition

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • National MS Center Melsbroek

    Melsbroek, Vlaams Brabant, 1820

Other trials in Belgium

About this study

Official title: Graph-theoretical Analysis of Magnetoencephalographic Recordings as a Biomarker for Cognitive Deterioration in Multiple Sclerosis

In this study, 100 persons with Multiple Sclerosis and 50 matched controls will be examined with magnetoencephalography (MEG), magnetic resonance imaging (MRI) and cognitive tests. The primary hypothesis for the study is: Interhemispheric connectivity, determined using graph theoretic analysis (GTA) on source-reconstructed MEG data, is a biomarker for cognitive deterioration in MS, which has value at the individual patient level.

Read the detailed description

Procedures

Clinical assessment

  • Disease type (Progressive onset/Relapsing onset)
  • Disease phase (onset, relapsing remitting, secondary progressive, …)
  • EDSS measurement (standard in the neurological examination)
  • Time since last relapse (important for the exclusion criteria)
  • Medication
  • Level of education
  • Pre-morbid Intelligence Quotient (IQ)

Symbol Digit Modalities Test (SDMT) - screening

  • General
  • In the final design of this study, the investigators will screen our patient group using the Symbol Digit Modalities Test (SDMT), a fast (5 min) and easy test that has been shown to be predictive of general cognitive impairment in MS probably due to the importance of information processing speed in cognitive deterioration in MS.
  • This screening procedure will allow us to include an 'enriched' sample of MS patients; i.e. including patients with different cognitive abilities will allow us to assess correlations between brain network organization and cognition over a broader range of cognitive abilities.

MEG/EEG assessment

  • General
  • The subjects are asked to come to the MEG unit in the Université libre de Bruxelles (ULB) Erasmus Hospital in Anderlecht
  • MEG measurements will be obtained using a Neuromag-306 Vector View system (Elekta). This scanner has 306 channels: 102 pairs of orthogonal planar gradiometers and 102 magnetometers. To aid artifact detection, electrooculograms (EOG) and electrocardiograms (ECG) were also recorded. Sampling frequency is 1000 Hertz (HZ).
  • Subjects will be monitored for excessive eye-blinks. Although methods as independent component analysis (ICA) can remove these artefacts to some extent, too many eye-blinks may render the subsequent analyses impossible.
  • Preparing the subject for the MEG assessment takes about 45 min.
  • The patient's head movement will be continuously monitored.
  • Resting-state
  • Eyes Open
  1. 10 min
  2. Subjects will be asked to pay attention to a fixation cross
  • Eyes Closed
  1. 10 min
  2. Subjects will be asked not to fall asleep
  • Adjusted SDMT
  • In this experiment, the patients are shown a code that links the numbers 1-9 to a certain symbol. For each trial, they also see one example that links a number to a symbol and they are asked to press the LEFT button if they think the example conforms with the presented code and the RIGHT button if they think otherwise. Subjects will be given a maximum of 6 s for each decision to be made and response timings will be recorded. The code that is presented varies with every example. This computerized set up of the SDMT was kindly provided by prof. Rypma. There is a pause of 2s between every decoding task. A total of 256 stimuli are presented, half of which are correct. The design follows the design by Leavitt et al. very closely (except for variable the interstimulus interval- 4,8,12 s - that was fixed to 3s in this design. Depending on the speed at which the subjects answers, this paradigm is expected to last between 9 and 10 min.
  • Practice trial
  1. The subjects are shown 10 trials and their response is monitored. In this step, the researcher checks if the subject understands the paradigm.
  • Actual paradigm
  1. The patients will be shown 256 trials, 50 % of which are correct.
  2. The total time for this experiment (at a speed of 2s per decision is : 9 min).
  3. The subjects won't receive any feedback from this part.
  • A small break of 10 minutes in order not to fatigue the subjects too much.
  • Auditory P300 paradigm
  • The subjects are asked to press a button when they hear a high-pitched tone among a series of standard tones. The interstimulus interval will randomly shift between 1 and 1.5 s.
  • Practice trial
  1. Subjects will first hear the standard tone 10 times (1000 Hz)
  2. Subjects will hear the target (high-pitched, 1500 Hz) tone 2 times
  3. Subjects will hear the distractor tone (500 Hz) 2 times
  4. The interstimulus interval will be sampled from the same distribution as the interstimulus interval used in the actual test
  5. Patients are not asked to press any buttons in this part.
  • Actual test
  1. The subjects will hear a series of 400 tones. The total test time is therefore 8m20.
  • 80 % of the tones will be frequent tones
  • 10 % of the tones will be target tones, for which the subjects are asked to press a button
  • 10 % of the tones will be distractor tones. Subjects are asked not to press any button in case of these distractor tones.
  • The subjects won't get any feedback on their performance
  • N-back test
  • In the N-back test, a subjects sees a series of numbers (1-4) and is asked to compare the current stimulus to the N'th previous stimulus. In the case of a zero-back experiment, the subjects are asked to press a button when they see a certain number (e.g. 2).
  • The experiment is designed as follows. There are three conditions imposing different loads on working memory (0-,1- and 2-back tasks). Each block lasts 30 s and there are eight blocks for each condition. The total registration time is therefore 12 min. The experiment is designed in agreement with the literature.
  • Before the actual experiment, there will be a small practice trial including the three blocks (0-, 1- and 2-back task). This lasts approximately 2 min.
  • Possible confounders:
  • General:
  1. These confounders are to be administered right after the MEG recordings.
  2. These confounders are important as they may influence the cognitive results obtained during the MEG.
  • Depression (Beck Depression Inventory)
  • Fatigue (Fatigue scale for Motor and Cognitive Functions, FSMC)
  • Brief International Cognitive Assessment for MS (BICAMS)
  • (2) MRI assessment
  • The informed consent asks for permission to analyse the T1 and T2 image, two images included in the standard clinical protocol, in the data analysis for the study. Furthermore, we will acquire and analyse a diffusor tensor imaging (DTI) measurement and a resting-state functional MRI image.
Keywords
Cognition, MEG
Medical subject headings
Multiple Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02851342
Study groupRoleWhat they receive
MSpatients with multiple sclerosis
COmatched control subjects

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MEG Contrasts of parameter estimates (COPE)

    Contrasts (first-level or group-level) of parameter estimates based on averaged measured magnetic activity.

    Measured: 0 to 1000 msec post stimulus

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2016 (estimated)
  2. Study startApr 2016
  3. Primary completionJan 2018
  4. Study completionJan 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
159 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02851342
Sponsor's protocol ID
BRUMEG
Status last verified
Nov 2020
First submitted
25 Jul 2016
Last updated
10 Nov 2020
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Multiple Sclerosis, run by Universitair Ziekenhuis Brussel at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MEG Contrasts of parameter estimates (COPE) (time frame: 0 to 1000 msec post stimulus). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in